Abnormal DNA methylation of the GATA5 gene promoter with subsequent loss of function has been previously reported in several cancers including esophageal, [30], gastric [31], colorectal, pancreatic, lung, and ovarian cancers [31], [32], [33], [34]. This evidence concerns the gene GATA5 and cancer.